| Characteristics of the primary tumor | <24 months | > 24 months | Total |
| Histological type | |||
| - IDC | 51 (41.8%) | 71 (58.2%) | 122 (100%) |
| - ILC | 33 (58.9%) | 23 (41.1%) | 56 (100%) |
| - Total | 84 | 94 | 178 |
| Clinical Stage | |||
| - I | 7 (25%) | 18 (72%) | 25 (100%) |
| - II | 25 (36.7%) | 43 (63.3%) | 68 (100%) |
| - III | 52 (61.1%) | 33 (38.9%) | 85 (100%) |
| - Total | 84 | 94 | 178 |
| Grade SBR | |||
| - I | 9 (2.9%) | 22 (97.1%) | 31 (100%) |
| - II | 28 (44.4%) | 35 (55.6%) | 63 (100%) |
| - III | 47 (55.9%) | 37 (44.1%) | 84 (100%) |
| - Total | 84 | 94 | 178 |
| Ki 67 | |||
| - Low | 6 (75%) | 2 (25%) | 8 (100%) |
| - Moderate | 13 (56.5%) | 10 (43.5%) | 23 (100%) |
| - High | 17 (62.9%) | 10 (37.1%) | 27 (100%) |
| - Total | 36 | 22 | 58 |
| HR | |||
| - Positive | 3 (25%) | 9 (75%) | 12 (100%) |
| - Negative | 38 (82.6%) | 8 (17.4%) | 46 (100%) |
| - Total | 41 | 17 | 58 |
| HER2 | |||
| - Positive | 8 (38.1%) | 13 (61.9%) | 21 (100%) |
| - Negative | 30 (81.1%) | 7 (18.9%) | 37 (100%) |
| - Total | 38 | 20 | 58 |